Applied Neuro Solutions
About Applied NeuroSolutions
Applied NeuroSolutions Team
Research & Development
Filings & Stock Data
Contact Us

Company Contact: John F. DeBernardis, Ph.D., President & CEO
(847) 573-8000

Investor Contact: Julie Huang or Courtney Wen, Financial Dynamics
(212) 850-5600

Media Contact:
Jeff Siegel, Monarch Communications
(516) 569-4271


Applied NeuroSolutions Retains FinancialDynamics as its Financial Communications and Investor Relations Agency

Vernon Hills, IL
, December 06, 2005 -
Applied NeuroSolutions, Inc. (OTC BB: APNS), a Company focused on the development of an integrated product portfolio for the diagnosis and treatment of Alzheimer's disease, today announced it has retained Financial Dynamics (FD), a leading full-service business communications consultancy, for investor relations counsel. FD will work with Applied NeuroSolutions’ management to develop and execute a comprehensive investor relations program designed to enhance Applied NeuroSolutions visibility within the investment community. Financial Dynamics’ responsibilities will include strategic counseling, investment community targeting and marketing and management of the quarterly earnings process.

John DeBernardis, Ph.D., President and Chief Executive Officer of Applied NeuroSolutions said, “We have made progress in our efforts to commercialize our lead product, a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage. As we look to maintain this momentum, we are very pleased to be working with Financial Dynamics on our investor relations program. Their deep industry knowledge and understanding of the issues and drivers which affect our key business audiences give us confidence in their ability to assist us in achieving our goal of communicating Applied NeuroSolutions’ story to the investment community.”

About Applied NeuroSolutions

Applied NeuroSolutions, Inc. (OTC BB: APNS) is developing products to diagnose and treat Alzheimer's disease based on a novel hypothesis of AD pathology. In partnership with Dr. Peter Davies and a scientific team at Albert Einstein College of Medicine, Applied NeuroSolutions has developed a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% accuracy in more than 3,000 patient samples. There are approximately 2 million new patients annually worldwide who are candidates for an AD CSF diagnostic test, according to Datamonitor. The company is also developing a blood serum-based screening test, as well as a new class of therapeutics to treat AD. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets ( USA, France, Germany, Italy, Spain, U.K. and Japan ) according to BioPortfolio, Ltd. For more information, visit

There are currently no FDA-approved diagnostic tests to detect Alzheimer's disease.

About Financial Dynamics (FD)

FD is a leading business communications and consulting firm with a 20 year history advising clients senior managements in corporate and financial public relations, investor relations, transaction communications public affairs and crisis communications. Co-headquartered in London and New York, FD provides seamless cross-border support through a network of offices across Europe, North America, Asia and the Middle East. FD recently formed a Business Consulting practice through the acquisition of management consulting firm Westhill Partners to provide clients with a broader range of solutions to address the critical business issues facing their organizations. The firm is structured around specialist sector teams operating on an international basis and is management owned in partnership with private equity firm Advent International. For more information, visit

This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at, and review the company's filings with the Securities and Exchange Commission.